Covalent Group, Inc. to Report Second Quarter 2005 Results on Thursday, August 11

Covalent Group, Inc. to Report Second Quarter 2005 Results on Thursday, August 11 


WAYNE, Pa., Aug. 1  /PRNewswire-FirstCall/ -- Covalent Group, Inc. (NASDAQ: CVGR) today announced that it will release financial results for the 2005 second quarter on Thursday, August 11, 2005, after market close with an accompanying conference call on Friday, August 12 at 9:00 a.m. ET.

To participate in the live call by telephone, please dial [phone] from the U.S., or for international callers, please dial [phone]. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Web site at http://www.covalentgroup.com/. Please go to the Web site 15 minutes prior to the scheduled start to register, download, and install any necessary audio software.

A webcast audio replay will be available on the Company Web site for 31 days through Monday, September 12, 2005.  A telephone audio replay will also be available for 10 days through Monday, August 22, 2005, by dialing [phone] from the U.S., or [phone] for international callers, and entering account number 3055 and conference ID number 163223 when prompted.

About Covalent Group

Covalent Group is a clinical research organization that is a leader in the design and management of complex clinical trials for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their clinical trials. Covalent offers therapeutic expertise, experienced team management and advanced technologies. The Company has clinical trial experience across a wide variety of therapeutic areas such as cardiovascular, endocrinology/metabolism, diabetes, vaccines, biologics, gene therapy, immunology, neurology, oncology, infectious diseases, gastroenterology, dermatology, hepatology, women's health and respiratory medicine.  Covalent believes that its leadership in the design of complex clinical trials, its application of innovative technologies, therapeutic expertise and commitment to quality offer its clients a means to more quickly and cost effectively develop products through the clinical trial process.  With its wholly-owned international subsidiary, Covalent Group, Ltd., as well as its Strategic Partners operating in various regions around the world, Covalent is able to meet the global drug development needs of its clients.

  Investor Relations Contact:
   Lawrence Hoffman, CPA, Esq.
   CFO, Covalent Group, Inc.
   [phone]
   Contact us on-line: http://www.covalentgroup.com/

DATASOURCE: Covalent Group, Inc.



CONTACT:  Lawrence Hoffman, CPA, Esq., CFO, Covalent Group, Inc.,

[phone]



Web site:  http://www.covalentgroup.com/ 

Copyright